Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Transferable Trustworthy Radiotherapy with Artificial Intelligence

Ziel

Cancer is the leading cause of death in Europe and the second worldwide. Over 50% of patients are treated with Radiotherapy (RT) and it accounts for 40% of cures, yet recurrence and toxicities remain significant challenges. Despite major advances in imaging, planning and delivery, RT still largely follows a “one-dose-fits-all” approach, leading to variable outcomes, toxicities and limited adaptability to patient-specific biology. Europe is currently undergoing a digital transformation driven by AI, advanced imaging and the European Health Data Space, but current AI solutions in RT remain fragmented, poorly generalizable and insufficiently explainable, preventing their safe deployment in clinical practice.
TTRAIL aims at improving the safety, precision and personalization of radiotherapy (RT) by training 15 Doctoral Candidates as the first generation of Translational AI Radiotherapy Scientists, capable of uniting AI innovation with clinical radiotherapy, medical physics, regulatory science and digital-health translation. Their training will span multiscale data integration, uncertainty quantification, explainable and causal outcome modelling, digital twins and real-time adaptive dose delivery, aligned with the EU AI Act.
The consortium unites top European universities, engineering schools, cancer centers and major industrial partners, providing access to cutting-edge RT platforms, large multicentre datasets and expertise across AI, imaging, oncology, physics and regulatory compliance. This intersectoral ecosystem ensures robust scientific training, clinical immersion, industrial exposure and strong open-science practices.
By delivering a fully integrated, trust-by-design framework for AI-enabled Adaptive Radiotherapy, TTRAIL will produce highly skilled researchers able to lead the future of personalised, safe and explainable cancer treatment in Europe.

Wissenschaftliches Gebiet (EuroSciVoc)

Dieses Projekt wurde noch nicht bei EuroSciVoc klassifiziert.
Schlagen Sie die Wissenschaftsbereiche vor, die Ihrer Einschätzung nach besonders relevant sind, und helfen Sie uns, unseren Klassifizierungsdienst zu verbessern.

Schlüsselbegriffe

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral Networks

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) HORIZON-MSCA-2025-DN-01

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Koordinator

UNIVERSITE DE RENNES
Netto-EU-Beitrag
€ 629 338,32
Adresse
263 AVENUE DU GENERAL LECLERC
35042 Rennes
Frankreich
Region
Bretagne Bretagne Ille-et-Vilaine
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
Keine Daten

Beteiligte (10)

Partner (13)